COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,889 Articles (22,568 medRxiv, 8,321 bioRxiv)

Most recent first Previous |  Page 2757: Articles 27561-27570  | Next

Meta-analysis of transcriptomes of SARS-Cov2 infected human lung epithelial cells identifies transmembrane serine proteases co-expressed with ACE2 and biological processes related to viral entry, immunity, inflammation and cellular stress.
Wruck, W., Adjaye, J.
10.1101/2020.05.12.091314 — Posted: 2020-05-13
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate
Ko, M., Jeon, S., Ryu, W.-S., Kim, S.
10.1101/2020.05.12.090035 — Posted: 2020-05-12
Mutation landscape of SARS-CoV-2 reveals three mutually exclusive clusters of leading and trailing single nucleotide substitutions
Mishra, A., Pandey, A. K., Gupta, P., Pradhan, P., Dhamija, S., Gomes, J., Kundu, B., Vivekanandan, P., Menon, M. B.
10.1101/2020.05.07.082768 — Posted: 2020-05-12
Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men
Ghazizadeh, Z., Majd, H., Richter, M., Samuel, R., Zekavat, S. M., Asgharian, H., Farahvashi, S., Kalantari, A., Ramirez, J., Zhao, H., Natarajan, P., Goodarzi, H., Fattahi, F.
10.1101/2020.05.12.091082 — Posted: 2020-05-12 Discussion: Onsite | Offsite
Children's Hospital Los Angeles COVID-19 Analysis Research Database (CARD) - A Resource for Rapid SARS-CoV-2 Genome Identification Using Interactive Online Phylogenetic Tools
Shen, L., Maglinte, D., Ostrow, D., Pandey, U., Bootwalla, M., Ryutov, A., Govindarajan, A., Ruble, D., Han, J., Triche, T. J., Dien Bard, J., Biegel, J. A., Judkins, A. R., Gai, X.
10.1101/2020.05.11.089763 — Posted: 2020-05-12
Static All-Atom Energetic Mappings of the SARS-Cov-2 Spike Protein with Potential Latch Identification of the Down State Protomer
Peters, M. H., Bastidas, O.
10.1101/2020.05.12.091090 — Posted: 2020-05-12
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P., Caniels, T., van Straten, K., Snitselaar, J., Aldon, Y., Bangaru, S., Torres, J., Okba, N., Claireaux, M., Kerster, G., Bentlage, A., van Haaren, M., Guerra, D., Burger, J., Schermer, E., Verheul, K., van der Velde, N., van der Kooi, A., van Schooten, J., van Breemen, M., Bijl, T., Sliepen, K., Aartse, A., Derking, R., Bontjer, I., Kootstra, N., Wiersinga, J., Vidarsson, G., Haagmans, B., Ward, A., de Bree, G., Sanders, R., van Gils, M.
10.1101/2020.05.12.088716 — Posted: 2020-05-12
Antiviral options against SARS-CoV-2 infection
Ianevski, A., Yao, R., Fenstad, M. H., Biza, S., Zusinaite, E., Lysvand, H., Loeseth, K., Lamndsem, V. M., Malmring, J. F., Oksenych, V., Erlandsen, S. E., Aas, P. A., Hagen, L., Pettersen, C. H., Afset, J. E., Nordbo, S. A., Bjoras, M., Kainov, D. E.
10.1101/2020.05.12.091165 — Posted: 2020-05-12
Performance of the rapid Nucleic Acid Amplification by Abbott ID NOW COVID-19 in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution
Basu, A., Zinger, T., Inglima, K., Woo, K.-m., Atie, O., Yurasits, L., See, B., Aguero-Rosenfeld, M. E.
10.1101/2020.05.11.089896 — Posted: 2020-05-12 Discussion: Onsite | Offsite
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual
Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., Nelson, R., Singh, S., Cohen, K. W., McElrath, J. M., Englund, J. A., Chu, H. Y., Pancera, M., McGuire, A. T., Stamatatos, L.
10.1101/2020.05.12.091298 — Posted: 2020-05-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).